Metronomic Chemotherapy in Pediatric Oncology: From Preclinical Evidence to Clinical Studies

Cyclic Metronomic Chemotherapy for Pediatric Tumors: Six Case Reports and a Review of the Literature

(2022) Benjamin Carcamo et al.   Journal of Clinical Medicine

Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial

(2022) Arif Manji et al.   Cancers

Quality of life in paediatric solid tumours: a randomised study of metronomic chemotherapy versus placebo

(2021) Raja Pramanik et al.   BMJ Supportive & Palliative Care

Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium

(2021) Claudia Pasqualini et al.   EUROPEAN JOURNAL OF CANCER

Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

(2020) Patrick Brown et al.   Journal of the National Comprehensive Cancer Network

Medical Care Costs Associated with Cancer Survivorship in the United States

(2020) Angela B. Mariotto et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Metro‐SMHOP 01: Metronomics combination with cyclophosphamide‐etoposide and valproic acid for refractory and relapsing pediatric malignancies

(2020) Maria El kababri et al.   PEDIATRIC BLOOD & CANCER

Opioid receptors beyond pain control: The role in cancer pathology and the debated importance of their pharmacological modulation

(2020) Marco Carli et al.   PHARMACOLOGICAL RESEARCH

Metronomic Maintenance With Weekly Vinblastine After Induction With Bevacizumab-Irinotecan in Children With Low-grade Glioma Prevents Early Relapse

(2020) Clémence Roux et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

SFCE METRO‐01 four‐drug metronomic regimen phase II trial for pediatric extracranial tumor

(2019) Marie‐Amélie Heng‐Maillard et al.   PEDIATRIC BLOOD & CANCER

Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition

(2019) Aida Karachi et al.   NEURO-ONCOLOGY

Metronomic therapy in pediatric oncology: A snapshot

(2019) Raja Pramanik et al.   PEDIATRIC BLOOD & CANCER

Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial

(2019) Gianni Bisogno et al.   LANCET ONCOLOGY

Does metronomic chemotherapy induce tumor angiogenic dormancy? A review of available preclinical and clinical data

(2018) Gianfranco Natale et al.   CANCER LETTERS

Update on neuroblastoma

(2018) Erika A. Newman et al.   JOURNAL OF PEDIATRIC SURGERY

Pediatric Brain Tumors

(2018) Yoko T. Udaka et al.   NEUROLOGIC CLINICS

Metronomic Four-Drug Regimen Has Anti-tumor Activity in Pediatric Low-Grade Glioma; The Results of a Phase II Clinical Trial

(2018) Arnauld Verschuur et al.   Frontiers in Pharmacology

Asparagine synthetase: Function, structure, and role in disease

(2017) Carrie L. Lomelino et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

International incidence of childhood cancer, 2001–10: a population-based registry study

(2017) Eva Steliarova-Foucher et al.   LANCET ONCOLOGY

Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide

(2017) Laura Ferrer-Font et al.   NMR IN BIOMEDICINE

Genome-wide loss-of-function genetic screening identifies opioid receptor μ1 as a key regulator of L-asparaginase resistance in pediatric acute lymphoblastic leukemia

(2017) S M Kang et al.   ONCOGENE

Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALK F1174L Drug-Resistant Neuroblastoma Preclinical Models

(2017) Libo Zhang et al.   Translational Oncology

Tumor response of temozolomide in combination with morphine in a xenograft model of human glioblastoma

(2017) Anna Lisa Iorio et al.   Oncotarget

Low dose of 2-deoxy-D-glucose kills acute lymphoblastic leukemia cells and reverses glucocorticoid resistance via N-linked glycosylation inhibition under normoxia

(2017) Ling Gu et al.   Oncotarget

A ketogenic diet supplemented with medium-chain triglycerides enhances the anti-tumor and anti-angiogenic efficacy of chemotherapy on neuroblastoma xenografts in a CD1-nu mouse model

(2017) Sepideh Aminzadeh-Gohari et al.   Oncotarget

Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors

(2017) Raja Pramanik et al.   JAMA Oncology

Metronomic Chemotherapy and Palliative Radiotherapy as Salvage Treatment of Refractory or Relapsed Pediatric Solid Tumors

(2016) A.M. Ali et al.   Current Oncology

Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect

(2016) Guido Bocci et al.   Nature Reviews Clinical Oncology

Schedule-Dependent Antiangiogenic and Cytotoxic Effects of Chemotherapy on Vascular Endothelial and Retinoblastoma Cells

(2016) Ursula Winter et al.   PLoS One

Combination of metronomic cyclophosphamide and dietary intervention inhibits neuroblastoma growth in a CD1-nu mouse model

(2016) Raphael Johannes Morscher et al.   Oncotarget

Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors

(2016) Kieuhoa T. Vo et al.   Oncotarget

A clinically attainable dose of L-asparaginase targets glutamine addiction in lymphoid cell lines

(2015) Koichi Sugimoto et al.   CANCER SCIENCE

Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models

(2015) L. Zhang et al.   CLINICAL CANCER RESEARCH

Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence

(2015) Sabine Taschner-Mandl et al.   Oncotarget

Maintenance chemotherapy in children with ALL exerts metronomic-like thrombospondin-1 associated anti-endothelial effect

(2015) Nicolas Andre et al.   Oncotarget

Treatment of Retinoblastoma in 2015

(2015) David H. Abramson et al.   JAMA Ophthalmology

Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8+T-cell responses and immune memory

(2015) Junjie Wu et al.   OncoImmunology

Pilot study of a pediatric metronomic 4-drug regimen

(2015) Nicolas André et al.   Oncotarget

Intermittent Metronomic Drug Schedule Is Essential for Activating Antitumor Innate Immunity and Tumor Xenograft Regression

(2015) Chong-Sheng Chen et al.   NEOPLASIA

Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model

(2014) Junjie Wu et al.   CANCER LETTERS

Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program

(2014) M. A. Smith et al.   CLINICAL CANCER RESEARCH

Secondary malignancies in pediatric cancer survivors: Perspectives and review of the literature

(2014) Daniel K. Choi et al.   INTERNATIONAL JOURNAL OF CANCER

Metronomics: towards personalized chemotherapy?

(2014) Nicolas André et al.   Nature Reviews Clinical Oncology

Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma

(2014) Teresa Delgado-Goñi et al.   NMR IN BIOMEDICINE

Tumor Dynamics in Response to Antiangiogenic Therapy with Oral Metronomic Topotecan and Pazopanib in Neuroblastoma Xenografts

(2014) Sushil Kumar et al.   Translational Oncology

Preliminary evaluation of children treated with metronomic chemotherapy and valproic acid in a low-income country: Metro-Mali-02

(2013) F Traore et al.   INDIAN JOURNAL OF CANCER

HIF-1α activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts

(2013) Joseph Hartwich et al.   JOURNAL OF PEDIATRIC SURGERY

Has the time come for metronomics in low-income and middle-income countries?

(2013) Nicolas André et al.   LANCET ONCOLOGY

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

(2013) J. Murai et al.   MOLECULAR CANCER THERAPEUTICS

A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer

(2013) Nathan J. Robison et al.   PEDIATRIC BLOOD & CANCER

VEGF Receptor Inhibitors Block the Ability of Metronomically Dosed Cyclophosphamide to Activate Innate Immunity-Induced Tumor Regression

(2012) J. C. Doloff et al.   CANCER RESEARCH

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH

Retinoblastoma

(2012) Helen Dimaras et al.   LANCET

Predicting Enhanced Cell Killing through PARP Inhibition

(2012) J. K. Horton et al.   MOLECULAR CANCER RESEARCH

Concise Drug Review: Pazopanib and Axitinib

(2012) R. M. J. M. van Geel et al.   ONCOLOGIST

Metronomic Chemotherapy with the COMBAT Regimen in Advanced Pediatric Malignancies: A Multicenter Experience

(2012) D. Zapletalova et al.   ONCOLOGY

Hypoxia suppresses conversion from proliferative arrest to cellular senescence

(2012) O. V. Leontieva et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mitoxantrone Inhibits HIF-1  Expression in a Topoisomerase II-Independent Pathway

(2011) Y.-M. Toh et al.   CLINICAL CANCER RESEARCH

Metronomic Oral Topotecan with Pazopanib Is an Active Antiangiogenic Regimen in Mouse Models of Aggressive Pediatric Solid Tumor

(2011) S. Kumar et al.   CLINICAL CANCER RESEARCH

Inhibition of tumors cell growth in osteosarcoma-bearing SD rats through a combination of conventional and metronomic scheduling of neoadjuvant chemotherapy

(2010) Xiao-zhong Zhu et al.   ACTA PHARMACOLOGICA SINICA

Children Treated With Metronomic Chemotherapy in a Low-income Country

(2010) Traore Fousseyni et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model

(2009) Claire Banissi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

(2009) A. Rapisarda et al.   MOLECULAR CANCER THERAPEUTICS

Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1  and -2 

(2008) M. Puppo et al.   MOLECULAR CANCER THERAPEUTICS

Pediatric Soft Tissue Sarcomas

(2008) David M. Loeb et al.   SURGICAL CLINICS OF NORTH AMERICA